Stingray Therapeutics Overview

Stingray is developing potent and selective small molecule inhibitors of ENPP1. ENPP1 is the direct negative regulator of the STING pathway which is essential for innate immune response. We have generated promising preliminary data and expect to file our IND in March 2023.

Contact Information

Address: Salt Lake City, UT